Drugs / ORILANOLIMAB
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03643627 | Aug 2016 → Apr 2017 | — | Syntimmune, Inc. | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04730804 | Mar → Dec 2021 | — | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05254613 | Nov 2019 → Jan 2021 | — | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03075878 | Jan 2018 → Apr 2019 | autoimmune hemolytic anemia, warm type | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03075904 | Jul 2017 → Jan 2019 | pemphigus foliaceus, pemphigus vulgaris | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04956276 | Jan → Jul 2022 | autoimmune hemolytic anemia, warm type | Alexion Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04982289 | Jan 2022 → Jan 2023 | generalized myasthenia gravis | Alexion Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04256148 | Jul 2021 → Oct 2022 | autoimmune hemolytic anemia, warm type | Alexion Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORILANOLIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298117 ↗ |
| Known as | ALXN1830 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03075904 ↗ |
| Known as | SYNT001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03643627 ↗ |
| Known as | SYNT1001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298117 ↗ |
| Action | Inhibit | “blocks neonatal Fc receptor interactions with IgG” PMID 34126109 ↗ Jun 20211“IgG receptor FcRn large subunit p51 antagonist” CHEMBL4298117 ↗ |
| Modality | Monoclonal antibody | “ALXN1830 is a humanized IgG4 antibody” PMID 34126109 ↗ Jun 2021 |
| Route | Intravenous | “Administered via IV infusion.” NCT03075878 ↗ |
| Target | FCGRT | “IgG receptor FcRn large subunit p51 antagonist” CHEMBL4298117 ↗ |